US equities
|
SPCX
$166.86
▲+4.97%
NVDA
$236.19
▲+0.96%
MU
$1,063.21
▼-1.09%
TSLA
$377.76
▲+1.93%
MSFT
$524.87
▲+1.42%
SNDK
$1,706.00
▼-0.81%
INTC
$117.09
▼-1.88%
META
$742.52
▲+1.98%
SPCX
$166.86
▲+4.97%
NVDA
$236.19
▲+0.96%
MU
$1,063.21
▼-1.09%
TSLA
$377.76
▲+1.93%
MSFT
$524.87
▲+1.42%
SNDK
$1,706.00
▼-0.81%
INTC
$117.09
▼-1.88%
META
$742.52
▲+1.98%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Mirum Pharmaceuticals, Inc. - common stock
(NQ:
MIRM
)
82.09
-0.84 (-1.01%)
Delayed Quote
Updated: 12:21 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Mirum Pharmaceuticals, Inc. - common stock
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 10, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
August 28, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 09, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
MIRM Stock Earnings: Mirum Pharmaceuticals Misses EPS, Beats Revenue for Q2 2024
↗
August 07, 2024
MIRM stock results show that Mirum Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Analyst Ratings For Mirum Pharmaceuticals
↗
May 09, 2024
Via
Benzinga
Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
August 07, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024
July 31, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum’s LIVMARLI Now Approved for PFIC in Patients 12 Months and Older
July 25, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 10, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals’ LIVMARLI Approved in the European Union for Patients with PFIC
July 08, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX
June 28, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Nvidia To Rally Around 53%? Here Are 10 Top Analyst Forecasts For Tuesday
↗
June 18, 2024
Via
Benzinga
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
June 17, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
↗
June 17, 2024
Via
Benzinga
Mirum Pharmaceuticals Highlights Encouraging Data For Rare Liver Disease Therapy From Two Mid-Stage Studies
↗
June 17, 2024
Mirum Pharmaceuticals announced promising interim results from Phase 2b studies of volixibat for primary biliary cholangitis and primary sclerosing cholangitis. Significant improvements in pruritus and...
Via
Benzinga
Aaron's, Nvidia, Mirum Pharmaceuticals, Primo Water And Other Big Stocks Moving Higher On Monday
↗
June 17, 2024
Via
Benzinga
Mirum’s Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies
June 17, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024
June 16, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 10, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC Highlighted at EASL Congress
June 06, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older
May 31, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress
May 29, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals’ LIVMARLI Data Showcased at ESPGHAN Annual Meeting
May 18, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 10, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
MIRM Stock Earnings: Mirum Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
↗
May 08, 2024
MIRM stock results show that Mirum Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
May 08, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
May 07, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC
May 07, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
May 01, 2024
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
